Close Menu

single molecule array

The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.

Quanterix Plans IPO

The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.

The funding was led by T. Rowe Price and will be used by Quanterix to develop new instruments, expand the firm's assay menu, and other things. 

ImmunArray will use Quanterix's Simoa single-molecule array technology for biomarker analysis, with the potential to enrich its diagnostic panels.

The company will develop the assays for its single-molecule array technology and incorporate the markers into multiplex assays for research use in neurology.

Three new investors joined existing investors in leading the round, which will fund desktop instrument development, international sales, and assay menu expansion.

As Quanterix continues to grow its business, quantifying proteins in single cells could drive its sales in the academic market, CEO Kevin Hrusovsky said.

The firm has signed an exclusive agreement for China with Cold Spring Biotech and a deal for Singapore, Thailand, and Malaysia with Research Instruments.

The firm has re-engineered hardware and redesigned software to improve its single-molecule array platform and has increased its multiplexing capabilities.

Quanterix has won a second GE NFL Head Health Challenge I grant and will use it to develop diagnostics with biomarkers discovered under the first grant.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.